Prof Thomas Borody, MB, BS, BSc(Med), MD, PhD, DSc, FRACP,FACP,FACG, AGAF,FRSN
Tom Borody was born in Krakow. His family emigrated from Poland in 1960, and settled in Sydney where the three children Edith, Ian and Tom completed Medicine at the UNSW and pursued General Practice, Obstetrics & Gynaecology, and Gastroenterology respectively.
Dr Thomas Borody completed his BSc(Med) and later MB BS graduating in 1974. He gained experience in parasitology, treatment of TB and leprosy in the Solomon Islands, completed his MD at the Garvan Institute of Medical Research and University of Sydney School of Veterinary Science, then spent 3y in clinical research at the Mayo Clinic, Rochester, Minnesota. Later he gained his PhD at the University of Newcastle and his DSc at UTS in Sydney. Dr Borody’s clinical interests focus on the development of novel treatments including those involving the human gut microbiome using Faecal Microbiota Transplantation(FMT) to treat Clostridium difficile infection(CDI), colitis, irritable bowel syndrome as well as neurologic and autoimmune disorders. His first FMT in 1988 on a patient with colitis cleared up her condition for over 25 years. To date Dr Borody’s Clinic has been has completed close to 14,000 FMT treatments.
In Krakow, 1889 Walery Jaworski described Vibrio rugola, later renamed Helicobacter pylori. In 1985 Borody pioneered the first effective triple antibiotic therapy for Helicobacter pylori, which cured hundreds of patients of their ulcers, prevented a calculated 18,655 premature deaths, and saved $10.03Billion in health costs in Australia alone. It was later marketed in the US as Helidac. An improvement, called quad therapy in now marketed as Pylera, and the next generation treatment for resistant Helicobacter pylori, Talicia, licensed to Redhill Biopharma has completed Phase III trials. Borody also developed a Crohn’s disease anti-Mycobacterium treatment which completed pivotal trials, and also colonoscopy bowel prep products Glycoprep, Glycoprep C, Moviprep and a capsule prep licensed to Salix, currently in clinical development. His FMT ‘crapsule’ is in multicentre CDI trials across the US, where he works closely with the Finch Therapeutic Group.
In 1984 Borody established the Centre for Digestive Diseases (CDD) in Sydney, Australia and has overseen its growth into an active clinical research institute with 72 employees. He has published more than 280 papers and filed 163 patents.